This document discusses various protocols for anticoagulation during hemodialysis. It begins by noting that patients on hemodialysis are at risk of both bleeding and thrombosis. It then outlines several protocols for anticoagulation including unfractionated heparin (UFH) administered via constant infusion or intermittent bolus, and low molecular weight heparin (LMWH). LMWH has benefits over UFH like longer half-life and more predictable effects, but is also more expensive. The document also discusses heparin-free dialysis, regional citrate anticoagulation, and other alternatives to standard heparin protocols. Selection of the optimal anticoagulation method requires consideration of individual patient
Renal Replacement Therapy: modes and evidenceMohd Saif Khan
Renal replacement therapy is a supportive care often required in critically ill patients who develop acute renal failure and its complications. Complexity arises when such patients become hemodynamically unstable and pose special challenge to critical care clinicians in ICU to carefully choose dialytic modality to tackle volume and solute overload. This presentation is about short description of modalities of RRT and current evidence regarding initiation, dose and type of modality.
Establishing and maintaining normal extracellular volume (ECV) is required to achieve normotension. The achievement of an optimal fluid status, as expressed by "dry weight" (DW), should allow for controlling blood pressure (BP) in the large majority of HD patients
Renal Replacement Therapy: modes and evidenceMohd Saif Khan
Renal replacement therapy is a supportive care often required in critically ill patients who develop acute renal failure and its complications. Complexity arises when such patients become hemodynamically unstable and pose special challenge to critical care clinicians in ICU to carefully choose dialytic modality to tackle volume and solute overload. This presentation is about short description of modalities of RRT and current evidence regarding initiation, dose and type of modality.
Establishing and maintaining normal extracellular volume (ECV) is required to achieve normotension. The achievement of an optimal fluid status, as expressed by "dry weight" (DW), should allow for controlling blood pressure (BP) in the large majority of HD patients
A very simple yet comprehensive presentation to understand the concept of CRRT and its implementation in Intensive Care Unit. Intended for the very beginners in ICU. After going through the presentation you will be able to say "Now I know it!"
A very simple yet comprehensive presentation to understand the concept of CRRT and its implementation in Intensive Care Unit. Intended for the very beginners in ICU. After going through the presentation you will be able to say "Now I know it!"
An update of this lecture is available at: https://www.slideshare.net/MohammedGawad/membranous-nephropathy-234601451
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Venous thromboembolism (VTE) is a disorder that includes deep vein thrombosis and pulmonary embolism. A deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, usually in the lower leg, thigh, or pelvis.
Heparin /certified fixed orthodontic courses by Indian dental academy Indian dental academy
The Indian Dental Academy is the Leader in continuing dental education , training dentists in all aspects of dentistry and offering a wide range of dental certified courses in different formats.
Indian dental academy provides dental crown & Bridge,rotary endodontics,fixed orthodontics,
Dental implants courses.for details pls visit www.indiandentalacademy.com ,or call
00919248678078
Cardiorenal Syndrome (Clinical Implications and Treatment Strategies) - Dr. G...NephroTube - Dr.Gawad
- Recorded videos of this lecture:
Arabic Language version of this lecture is available at:
https://youtu.be/8eePyMbbK_g
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
- Video recording of this lecture in English language: https://youtu.be/gnlRvJ1TTr8
- Video recording of this lecture in Arabic language: https://youtu.be/KdVvfP7JIFI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
- Video recording of this lecture in English language: https://www.youtube.com/watch?v=MA7nU5NWL2g&list=PLL7Q08IoVDSpg0VlGdvCHOHbXqMs0GFRe
- Video recording of this lecture in Arabic language: https://www.youtube.com/watch?v=FiWabzTPFqY&list=PLL7Q08IoVDSrVcm6SmppQyefL_Ub2-xGY
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
- Recorded video of this lecture is available at:
https://youtu.be/4MCu1C5xjvE
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
- Recorded videos of this lecture:
English Language version of this lecture is available at: https://youtu.be/YT5IlPs6F0I
Arabic Language version of this lecture is available at: https://youtu.be/HUZt4ahXlxo
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Thrombotic Microangiopathy (TMA) in Adults and Acute Kidney Injury - Dr. GawadNephroTube - Dr.Gawad
- English version of this lecture is available at:
https://youtu.be/zrFm0hAZk2A
- Arabic version of this lecture is available at:
https://youtu.be/M_BV8WJVbx0
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
- English version of this lecture is available at:
https://youtu.be/V3UGzJTwAWw
- Arabic version of this lecture is available at:
https://youtu.be/hGLaUde2ue4
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
- English version of this lecture is available at:
https://youtu.be/t7N2GSXhYwA
- Arabic version of this lecture is available at:
https://youtu.be/WzFZym9hDtQ
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
- English version of this lecture is available at:
https://youtu.be/XRD-QqGFP18
- Arabic version of this lecture is available at:
https://youtu.be/c9PoavAtNKM
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Infection-related Glomerulonephritis (KDIGO 2021 Guidelines) - Dr. GawadNephroTube - Dr.Gawad
- English version of this lecture is available at:
https://youtu.be/qItQlXUC2-Q
- Arabic version of this lecture is available at:
https://youtu.be/goKWRFbA4uc
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
- English version video of this lecture is available at:
https://youtu.be/z9P_1IiFR5I
- Arabic version video of this lecture is available at:
https://youtu.be/qmDeWgsAY9Q
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
- English version of this lecture is available at:
https://youtu.be/lvcXwE0fb-w
- Arabic version of this lecture is available at:
https://youtu.be/r-fG8bSCqZo
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
- English version of this lecture is available at: https://youtu.be/_Efu52kZRS4
- Arabic version of this lecture is available at: https://youtu.be/8eGHpjQIy3I
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
- English version of this lecture is available at: https://youtu.be/WHu05hmExBY
- Arabic version of this lecture is available at: https://youtu.be/GIvZjcq2Eis
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Insights from the FIGARO-DKD and FIDELIO-DKD trials - Dr. GawadNephroTube - Dr.Gawad
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/kanEHVsStsI
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Diabetes Mellitus Management in CKD (Clinical Tips) - Dr. GawadNephroTube - Dr.Gawad
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/h3HRvWGUj5A
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Hemodialysis Anticoagulation - Different Protocols / Protocol Selection - Dr. Gawad
1. Hemodialysis Anticoagulation
Different Protocols / Protocol Selection
Mohammed Abdel Gawad
Nephrology Specialist
Kidney & Urology Center (KUC)
Alexandria – EGY
drgawad@gmail.com
UNC, Mansoura, International Hemodialysis Course
13-18 Dec 2015
2. To download the full animated lecture
please contact me on
drgawad@gmail.com
Visit www.NephroTubeCNE.com for
more lectures
3. Patients on Hemodialysis are at risk of
both bleeding tendency & thrombosis
• uremia-associated
platelet dysfunction
• endothelial
abnormalities.
• anticoagulants on
HD
• systemic inflammation
• diffuse endothelial damage.
• ↓proteins C and S,
antithrombin III levels &
activity.
• HD filters and lines
• Turbulent blood flow and
high shear stress during HD.
• leukocytes and platelets
coaggregate
• high hematocrit
• blood transfusions.
Bleeding Thrombosis
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
4. Pharmacology, 5th edition. Lippincott Williams & Wilkins. Chapter 20, IV. 2012
Image reference: Bombeli T, Spahn DR. Br J Anaesth. 2004 Aug;93(2):275-87
5. Pharmacology, 5th edition. Lippincott Williams & Wilkins. Chapter 20, IV. 2012
Image reference: Bombeli T, Spahn DR. Br J Anaesth. 2004 Aug;93(2):275-87
8. UFH
Pharmacology, 5th edition. Lippincott Williams & Wilkins. Chapter 20, IV. 2012
Image reference: Bombeli T, Spahn DR. Br J Anaesth. 2004 Aug;93(2):275-87
9. Pharmacology, 5th edition. Lippincott Williams & Wilkins. Chapter 20, IV. 2012
Image reference: Brayan F. etal. Am Fam Physician. 1999 Feb 15;59(4):945-952.
10. Heparin Administration Methods
Initial Bolus Followed by
Method A Routine heparin constant-infusion method
Method B Routine heparin single-dose-only
or repeated-bolus method
Method C Tight heparin constant-infusion method
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
11. Heparin Administration Methods
Initial Bolus Followed by
Method A Routine heparin constant-infusion method
Method B Routine heparin single-dose-only
or repeated-bolus method
Method C Tight heparin constant-infusion method
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
12. A- Routine heparin, constant-infusion
method
Initial bolus dose Infusion dose
Intermittent HD
2000 IU 1,200 IU/hr
50 IU/kg 800–1500 IU/hr
CRRT
2000-5000 IU
(30 IU/kg)
500-1000 IU/hr
(5-10 IU/kg/hr)
Target: aPTT
45 to 60 sec
or 1.5 to 2.0 times
normal
ERBP. NDT, Volume 17 suppl 7 July 2002
ERBP. NDT, Volume 17 suppl 7 July 2002
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
15. A- Routine heparin, constant-infusion
method
Initial bolus dose Infusion dose
Intermittent HD 2000 IU 1,200 IU/hr
CRRT 2000-5000 IU
(30 IU/kg)
500-1000 IU/hr
(5-10 IU/kg/hr)
Target: aPTT
45 to 60 sec
or 1.5 to 2.0 times
normal
When to stop heparin infusion?
Stopping heparin infusion 1 hour prior to the end of
dialysis will result in the desired clotting time at
termination of the session
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
16. Heparin Monitoring – Clotting Tests
A- Routine heparin, constant-infusion
method
In practice heparin therapy is ordinarily
prescribed empirically, without monitoring of
coagulation
In patients who are at an elevated risk of
bleeding, the need to monitor anticoagulation is
often circumvented by using heparin-free
dialysis.
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
17. Heparin Administration Methods
Initial Bolus Followed by
Method A Routine heparin constant-infusion method
Method B Routine heparin single-dose-only
or repeated-bolus method
Method C Tight heparin constant-infusion method
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
18. B- Routine heparin, single-dose-only
or repeated-bolus method
Initial bolus dose Subsequent repeated boluses
4000 IU 1000-2000 IU when needed
2000 IU 1000 IU at start of 2nd hr
1000 IU at start of 3rd hr
1000 IU at start of 4th hr
2000 IU No repeated boluses
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
19. Heparin Administration Methods
Initial Bolus Followed by
Method A Routine heparin constant-infusion method
Method B Routine heparin single-dose-only
or repeated-bolus method
Method C Tight heparin constant-infusion method
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
20. C- Tight (Minimum-dose) heparin,
constant-infusion method
• Recommended for patients who are at
SLIGHT RISK for bleeding:
–when the risk of bleeding is chronic and
prolonged
–if the use of heparin-free dialysis has been
unsuccessful because of frequent clotting.
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
22. C- Tight (Minimum-dose) heparin,
constant-infusion method
Obtain baseline clotting time
Initial bolus dose = 750 IU
Recheck Clotting time after 3 minutes
Desired clotting time
Start dialysis and heparin infusion at a
rate of 600 IU/hr
Monitor clotting times every
30 minutes
Not desired clotting time
Administer a
supplemental bolus dose
Keep clotting time within
desired range
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
23. C- Tight (Minimum-dose) heparin,
constant-infusion method
When to stop heparin infusion?
Continue heparin infusion until the end of the dialysis
session
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
24. Clotting inspite of anticoagulation
Don’t always blame heparin
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
25. Clotting inspite of anticoagulation
Don’t always blame heparin
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
26. Clotting inspite of anticoagulation
Recurrent clotting warrants individual
reevaluation and adjustments in
heparin dosing
ERBP. NDT, Volume 17 suppl 7 July 2002
27. Complications of Heparinization
1- Bleeding
• Incidence of bleeding ranges from 10 to 50 %
• Mortality due to bleeding as high as 15 %
• The risk of bleeding is proportional to the
aPTT and not to the heparin dose
van de Wetering et al. J Am Soc Nephrol. 1996 Jan;7(1):145-50.
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
28. Complications of Heparinization
1- Bleeding
Post therapy needle puncture site bleeding
Don’t always blame heparin
• Re-evaluation of the heparin dose
• Vascular access should be evaluated for the presence
of outflow stenosis
• Evaluation of needle insertion technique
ERBP. NDT, Volume 17 suppl 7 July 2002
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
34. UFH
Pharmacology, 5th edition. Lippincott Williams & Wilkins. Chapter 20, IV. 2012
Image reference: Bombeli T, Spahn DR. Br J Anaesth. 2004 Aug;93(2):275-87
LMWH
35. Pharmacology, 5th edition. Lippincott Williams & Wilkins. Chapter 20, IV. 2012
Image reference: Brayan F. etal. Am Fam Physician. 1999 Feb 15;59(4):945-952.
36. LMWH vs UFH
• LMWH has:
– longer half-life
– more rapid onset of action
– higher bioavailability
– more predictable effects
Aggarwal A. Nephrol Dial Transplant. 2004;19:1559–1563.
Lai KN, et al. Int J Artif Organs. 2001;24:447.
37. LMWH vs UFH
• LMWH has:
– less nonspecific binding to the endothelium,
plasma proteins, and platelets
– less platelet and leukocyte activation and fibrin
deposition on dialyzer surfaces
– No antidote (not reversible with protamine)
Aggarwal A. Nephrol Dial Transplant. 2004;19:1559–1563.
Lai KN, et al. Int J Artif Organs. 2001;24:447.
38. LMWH vs UFH
• LMWH has:
– Less risk of heparin induced osteoporosis
– less bleeding and less thrombocytopenia (but HIT
occurs, due to cross-reactive Ab)
– Less hyperkalemia
– Less disturbance of lipid profile
– Anaphylactoid first dose syndrome (as UHF)
Kishimoto TK, et al. N Engl J Med. 2008;358:2457–2467.
Aggarwal A. Nephrol Dial Transplant. 2004;19:1559–1563.
Lai KN, et al. Int J Artif Organs. 2001;24:447.
ERBP. NDT, Volume 17 suppl 7 July 2002
39. LMWH vs UFH
J Am Soc Nephrol. 2004 Dec;15(12):3192-206.
Mean differences for bleeding assessed
as vascular access compression time
40. J Am Soc Nephrol. 2004 Dec;15(12):3192-206.
Relative risks for
extracorporeal
circuit
thrombosis
LMWH vs UFH
42. But as LMWHs are very expensive and have
generally not been found to be superior to UFH
in terms of dialysis-related bleeding
UFH is widely used
43. Commonly Used LMWHs
IHD dosing
Lower dosages should be used in patients who
have a mildly increased risk of hemorrhage.
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
44. Commonly Used LMWHs
IHD dosing
longer half-life → permits anticoagulation with a
single dose at the start of dialysis
though split dosing may be better for extended
dialysis sessions
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
45. Commonly Used LMWHs
CRRT dosing
Bolus Infusion
Dalteparin 20 U/kg 10 U/kg per hour
Sagedal S, Hartmann A. Eur J Med Res. 2004;9:125–130.
Oudemans-van Straaten HM, et al. Crit Care Med. 2009;37:545–552.
Enoxaparin and Nadroparin may be used, but
the experience is limited
46. Commonly Used LMWHs
CRRT dosing
Joannidis M et al. Intensive Care Med 2007; 33:1571.
Ashita J Tolwani, Keith M Wille. UpToDate. Nov 2015.
But generally LMWHs are not widely used in CRRT
because of a very prolonged half-life and may be
associated with a high risk of bleeding
No major benefit in terms of reduced bleeding
episodes or increased filter survival associated with
LMWH.
47. LMWHs Monitoring
• aPTT is not accurate with LMW heparin
• Measurement of anti-factor Xa levels provide
a better indication
• But coagulation tests are not routinely
monitored with LMWH treatments (anti-Xa
activity assays are not readily available)
Polkinghorne KR et al. Am J Kidney Dis. 2002;40(5):990.
50. Heparin-free dialysis - Indications
Persons with heparin allergy
ERBP. NDT, Volume 17 suppl 7 July 2002
Daugirdas. Handbook of dialysis. Chapter 14, 5th edition, 2015.
51. Heparin-free dialysis - Procedure
Heparin rinse: Rinse extracorporeal circuit
with saline containing 2000 to 5000 units of
heparin/L
Drain the heparin-containing priming fluid
by unheparinized saline at the outset of
dialysis.
Set the blood flow rate to 250-500 mL/min
Periodic saline rinse with 50-250 mL of
saline every 15-30 minutes
Stamatiadis DN et al. Clin Nephrol. 2004;62(1):29.
52. Heparin-free dialysis - Procedure
Heparin rinse: Rinse extracorporeal circuit
with saline containing 2000 to 5000 units of
heparin/L
Drain the heparin-containing priming fluid
by unheparinized saline at the outset of
dialysis.
Set the blood flow rate to 250-500 mL/min
Periodic saline rinse with 50-250 mL of
saline every 15-30 minutes
This step is optional.
Avoid if HIT
Allow inspection of
a hollow-fiber
dialyzer for evidence
of clotting
Stamatiadis DN et al. Clin Nephrol. 2004;62(1):29.
53. Heparin-free dialysis - CRRT
Predilution mode is preferred
(because prefilter fluid
replacement reduces the
hemoconcentration within the
hemofilter when plasma water
is removed)
Keeping the blood flows at 200
mL/min or higher
Joannidis M et al. Crit Care. 2007;11(4):218.
56. Regional anticoagulation with
protamine reversal
binds to heparin and eliminates
its anticoagulant activity
van der Voort PH et al. Blood Purif. 2005;23(3):175-80.
57. Regional anticoagulation with
protamine reversal
binds to heparin and eliminates
its anticoagulant activity
Technically difficult and rebound bleeding
two to four hours after the end of dialysis
van der Voort PH et al. Blood Purif. 2005;23(3):175-80.
61. Heparin coated filter
Evenepoel P et al. Am J Kidney Dis. 2007 May;49(5):642-9.
The coated membranes were associated with a
significantly increased incidence of membrane
clotting
68. Regional Citrate Anticoagulation
Stucker F et al. Crit Care. 2015;19(1):91.
Apsner R et al. Am J Kidney Dis. 2005;45(3):557
• It may cause alkalemia on a long-term basis
• Dialysis solution bicarbonate level should
be reduced
69. Regional Citrate Anticoagulation
The major problems:
• hypocalcemia or hypercalcemia
• hypernatremia (due to the hypertonic
sodium citrate solution)
• metabolic alkalosis
Stucker F et al. Crit Care. 2015;19(1):91.
Apsner R et al. Am J Kidney Dis. 2005;45(3):557
70. Regional Citrate vs Heparin
Anticoagulation
• RCA may reduce bleeding risk more.
• RCA has similar or better efficacy on circuit patency
depending.
• RCA may also reduce neutrophil and complement
activation in the extracorporeal circuit.
Wu MY, et al. Am J Kidney Dis. 2012;59:810–818.
Monchi M, et al. Intensive Care Med. 2004;30:260–265.
Schilder L, et al. BMC Nephrol. 2014;15:19.
76. Bicarbonate dialysis solution with
low-concentration citrate (Citrasate™)
A small amount of citric acid is used instead of acetic acid as
the acidifying agent.
acid and base concentrates are mixed
resulting dialysis solution commonly contains 0.8
mmol/L (2.4 mEq/L) citrate.
Citrate complexing with calcium → inhibit blood coagulation and
platelet activation locally at the dialyzer membrane surface
Ahmad S et al. Hemodial Int. 2005;9:264.
77. Bicarbonate dialysis solution with
low-concentration citrate (Citrasate™)
A small amount of citric acid is used instead of acetic acid as
the acidifying agent.
acid and base concentrates are mixed
resulting dialysis solution commonly contains 0.8
mmol/L (2.4 mEq/L) citrate.
Citrate complexing with calcium → inhibit blood coagulation and
platelet activation locally at the dialyzer membrane surface
Ahmad S et al. Hemodial Int. 2005;9:264.
Further studies are needed to delineate
the role of citric acid-based dialysates.
It is commercially available.
81. Their use is primary in management of HIT
Davenport. Semin Dial. 2011;24:382-385.
Linkins LA et al. American College of Chest Physicians. Chest. 2012;141(2 Suppl):e495S.
85. Their use is primary in management of HIT
Davenport. Semin Dial. 2011;24:382-385.
Linkins LA et al. American College of Chest Physicians. Chest. 2012;141(2 Suppl):e495S.
Bivalirudin aPPTr of around
1.5–2.0.
infusion rate is 1.0–2.5
mg/hour (0.009–0.023
mg/kg/hour) adjusted to
93. Platelet-inhibiting agents
• PGI2 and its synthetic derivative, Epoprostenol:
– inhibit platelet aggregation and adhesion
– PGI2 is a potent vasodilator, the risk of hypotension
• Nafamostat mesilate
– Synthetic serine protease inhibitor,
– It is a prostacyclin analog that does not cause
hypotension.
– Several side effects (anaphylaxis, agranulocytosis,
hyperkalemia) have been reported.
Balik M et al. Blood Purif. 2005;23(4):325-9. Epub 2005 Aug 23.
Higuchi N et al. Nephron. 2000 Nov;86(3):400-1.
94. Platelet-inhibiting agents
• PGI2 and its synthetic derivative, Epoprostenol:
– inhibit platelet aggregation and adhesion
– PGI2 is a potent vasodilator, the risk of hypotension
• Nafamostat mesilate
– Synthetic serine protease inhibitor,
– It is a prostacyclin analog that does not cause
hypotension.
– Several side effects (anaphylaxis, agranulocytosis,
hyperkalemia) have been reported.
There are only limited clinical experience
with prostacyclin and few published reports
of its safety and efficacy
Balik M et al. Blood Purif. 2005;23(4):325-9. Epub 2005 Aug 23.
Higuchi N et al. Nephron. 2000 Nov;86(3):400-1.